Addressing the immunopathogenesis of atopic dermatitis: Advances in topical and systemic treatment
Recommended Citation
Eichenfield LF, Stein Gold LF. Addressing the immunopathogenesis of atopic dermatitis: Advances in topical and systemic treatment. Semin Cutan Med Surg 2017; 36(Suppl 2):45S-48S.
Document Type
Conference Proceeding
Publication Date
3-2017
Publication Title
Semin Cutan Med Surg
Abstract
Several immunologic mediators—phosphodiesterase (PDE), interleukin (IL), small molecules, and Janus kinase—have been implicated in the pathogenesis of atopic dermatitis, and evidence has shown that blocking these mediators can help modify the disease process. Several new topical medications have been developed that target the enzyme PDE; crisaborole was recently approved by the US Food and Drug Administration (FDA) for the treatment of atopic dermatitis, and phase II studies have been completed on OPA-15406. The phase III clinical trial results of the systemic medication dupilumab, an inhibitor of the IL-4 receptor α subunit (which inhibits both IL-4 and IL-13 signaling), are currently being reviewed by the FDA.
Volume
36
Issue
Suppl 2
First Page
45S
Last Page
48S
